Akero, bruised from earlier failure, soars as liver scarring improves in longer MASH trial

Akero Therapeutics’ roller coaster ride has lurched once again. After a whiplash rise and fall, the biotech has bounced back with 96-week data linking its FGF21 analog efruxifermin to significant improvements in liver scarring in metabolic dysfunction-associated steatohepatitis (MASH).